WEBVTT
Kind: captions
Language: en

00:00:01.770 --> 00:00:06.260 

a<00:00:03.859> CT<00:00:04.859> is<00:00:05.069> a<00:00:05.100> company<00:00:05.580> that's<00:00:05.760> focused<00:00:06.120> on

00:00:06.260 --> 00:00:06.270 
a CT is a company that's focused on

00:00:06.270 --> 00:00:08.959 
a CT is a company that's focused on
regenerative<00:00:06.859> ophthalmology<00:00:07.859> we<00:00:08.250> have<00:00:08.549> to

00:00:08.959 --> 00:00:08.969 
regenerative ophthalmology we have to

00:00:08.969 --> 00:00:11.029 
regenerative ophthalmology we have to
keep<00:00:09.420> programs<00:00:09.869> right<00:00:10.080> now<00:00:10.230> in<00:00:10.379> Stargardt's

00:00:11.029 --> 00:00:11.039 
keep programs right now in Stargardt's

00:00:11.039 --> 00:00:14.269 
keep programs right now in Stargardt's
and<00:00:11.309> AMD<00:00:12.090> age-related<00:00:12.900> macular<00:00:13.559> degeneration

00:00:14.269 --> 00:00:14.279 
and AMD age-related macular degeneration

00:00:14.279 --> 00:00:17.029 
and AMD age-related macular degeneration
which<00:00:15.090> is<00:00:15.600> both<00:00:15.750> back<00:00:16.049> of<00:00:16.230> the<00:00:16.320> eye<00:00:16.350> disorders

00:00:17.029 --> 00:00:17.039 
which is both back of the eye disorders

00:00:17.039 --> 00:00:19.220 
which is both back of the eye disorders
both<00:00:17.640> Stargardt's<00:00:18.270> disease<00:00:18.270> which<00:00:18.990> is<00:00:19.140> an

00:00:19.220 --> 00:00:19.230 
both Stargardt's disease which is an

00:00:19.230 --> 00:00:22.370 
both Stargardt's disease which is an
orphan<00:00:19.380> indication<00:00:20.130> in<00:00:20.280> dry<00:00:20.700> AMD<00:00:21.260> result<00:00:22.260> from

00:00:22.370 --> 00:00:22.380 
orphan indication in dry AMD result from

00:00:22.380 --> 00:00:24.440 
orphan indication in dry AMD result from
the<00:00:22.560> loss<00:00:22.710> of<00:00:22.920> the<00:00:23.100> RPE<00:00:23.520> cells<00:00:23.700> in<00:00:24.300> the<00:00:24.420> eye

00:00:24.440 --> 00:00:24.450 
the loss of the RPE cells in the eye

00:00:24.450 --> 00:00:27.380 
the loss of the RPE cells in the eye
these<00:00:25.440> RPE<00:00:25.860> cells<00:00:26.010> are<00:00:26.490> the<00:00:26.580> nerve<00:00:26.850> cells<00:00:27.150> that

00:00:27.380 --> 00:00:27.390 
these RPE cells are the nerve cells that

00:00:27.390 --> 00:00:28.670 
these RPE cells are the nerve cells that
maintain<00:00:27.840> the<00:00:28.050> health<00:00:28.200> of<00:00:28.380> the<00:00:28.470> photo

00:00:28.670 --> 00:00:28.680 
maintain the health of the photo

00:00:28.680 --> 00:00:30.410 
maintain the health of the photo
receptors<00:00:29.250> which<00:00:29.640> are<00:00:29.730> the<00:00:29.850> cones<00:00:30.119> and<00:00:30.360> the

00:00:30.410 --> 00:00:30.420 
receptors which are the cones and the

00:00:30.420 --> 00:00:32.869 
receptors which are the cones and the
rods<00:00:30.660> that<00:00:30.900> we<00:00:31.020> see<00:00:31.260> with<00:00:31.289> so<00:00:32.160> in<00:00:32.460> order<00:00:32.699> to

00:00:32.869 --> 00:00:32.879 
rods that we see with so in order to

00:00:32.879 --> 00:00:35.600 
rods that we see with so in order to
treat<00:00:33.629> these<00:00:33.810> diseases<00:00:33.890> we<00:00:34.890> go<00:00:35.070> in<00:00:35.220> with<00:00:35.400> new

00:00:35.600 --> 00:00:35.610 
treat these diseases we go in with new

00:00:35.610 --> 00:00:37.700 
treat these diseases we go in with new
healthy<00:00:36.000> RPE<00:00:36.390> cells<00:00:36.570> that<00:00:36.989> would<00:00:37.140> derive<00:00:37.440> from

00:00:37.700 --> 00:00:37.710 
healthy RPE cells that would derive from

00:00:37.710 --> 00:00:42.530 
healthy RPE cells that would derive from
embryonic<00:00:38.040> stem<00:00:38.489> cells<00:00:38.730> a<00:00:39.530> CT<00:00:40.530> is<00:00:41.329> one<00:00:42.329> of<00:00:42.450> the

00:00:42.530 --> 00:00:42.540 
embryonic stem cells a CT is one of the

00:00:42.540 --> 00:00:45.920 
embryonic stem cells a CT is one of the
originator<00:00:43.110> of<00:00:43.610> cell<00:00:44.610> therapy<00:00:45.149> it's<00:00:45.420> based<00:00:45.780> on

00:00:45.920 --> 00:00:45.930 
originator of cell therapy it's based on

00:00:45.930 --> 00:00:48.170 
originator of cell therapy it's based on
the<00:00:45.989> work<00:00:46.170> of<00:00:46.320> dr.<00:00:46.649> Robert<00:00:46.950> Lanza<00:00:47.370> who

00:00:48.170 --> 00:00:48.180 
the work of dr. Robert Lanza who

00:00:48.180 --> 00:00:49.819 
the work of dr. Robert Lanza who
pioneered<00:00:48.510> a<00:00:48.840> lot<00:00:49.020> of<00:00:49.110> the<00:00:49.200> work<00:00:49.380> that<00:00:49.620> we're

00:00:49.819 --> 00:00:49.829 
pioneered a lot of the work that we're

00:00:49.829 --> 00:00:52.100 
pioneered a lot of the work that we're
conducting<00:00:50.579> here<00:00:51.059> the<00:00:51.510> kinds<00:00:51.840> of<00:00:51.899> macular

00:00:52.100 --> 00:00:52.110 
conducting here the kinds of macular

00:00:52.110 --> 00:00:54.860 
conducting here the kinds of macular
degeneration<00:00:52.350> that<00:00:53.130> we've<00:00:53.969> been<00:00:54.180> treating<00:00:54.780> in

00:00:54.860 --> 00:00:54.870 
degeneration that we've been treating in

00:00:54.870 --> 00:00:57.590 
degeneration that we've been treating in
our<00:00:54.960> clinical<00:00:55.320> trials<00:00:55.770> that<00:00:56.210> include<00:00:57.210> the<00:00:57.420> use

00:00:57.590 --> 00:00:57.600 
our clinical trials that include the use

00:00:57.600 --> 00:01:00.650 
our clinical trials that include the use
of<00:00:57.770> pigment<00:00:58.770> epithelial<00:00:59.340> cells<00:00:59.610> that<00:01:00.329> have

00:01:00.650 --> 00:01:00.660 
of pigment epithelial cells that have

00:01:00.660 --> 00:01:04.160 
of pigment epithelial cells that have
been<00:01:00.960> especially<00:01:01.710> created<00:01:02.700> to<00:01:03.120> treat<00:01:03.840> these

00:01:04.160 --> 00:01:04.170 
been especially created to treat these

00:01:04.170 --> 00:01:06.230 
been especially created to treat these
forms<00:01:04.500> of<00:01:04.619> macular<00:01:04.769> degeneration<00:01:05.070> the<00:01:06.060> eye<00:01:06.090> is

00:01:06.230 --> 00:01:06.240 
forms of macular degeneration the eye is

00:01:06.240 --> 00:01:08.480 
forms of macular degeneration the eye is
ideal<00:01:06.840> for<00:01:07.139> the<00:01:07.200> first<00:01:07.439> inhuman<00:01:07.920> application

00:01:08.480 --> 00:01:08.490 
ideal for the first inhuman application

00:01:08.490 --> 00:01:10.219 
ideal for the first inhuman application
of<00:01:08.609> embryonic<00:01:08.969> stem<00:01:09.299> cells<00:01:09.509> for<00:01:09.869> a<00:01:09.899> number<00:01:10.109> of

00:01:10.219 --> 00:01:10.229 
of embryonic stem cells for a number of

00:01:10.229 --> 00:01:12.410 
of embryonic stem cells for a number of
reasons<00:01:10.380> one<00:01:11.310> is<00:01:11.520> the<00:01:11.729> eye<00:01:11.759> is<00:01:11.909> immune

00:01:12.410 --> 00:01:12.420 
reasons one is the eye is immune

00:01:12.420 --> 00:01:14.719 
reasons one is the eye is immune
privileged<00:01:12.990> and<00:01:13.200> thus<00:01:13.649> has<00:01:13.950> an<00:01:14.100> attenuated

00:01:14.719 --> 00:01:14.729 
privileged and thus has an attenuated

00:01:14.729 --> 00:01:17.269 
privileged and thus has an attenuated
response<00:01:15.179> to<00:01:15.569> the<00:01:15.689> transplantation<00:01:16.319> of<00:01:16.619> cells

00:01:17.269 --> 00:01:17.279 
response to the transplantation of cells

00:01:17.279 --> 00:01:19.239 
response to the transplantation of cells
that<00:01:17.399> are<00:01:17.520> derived<00:01:18.149> using<00:01:18.450> this<00:01:18.719> technology

00:01:19.239 --> 00:01:19.249 
that are derived using this technology

00:01:19.249 --> 00:01:21.379 
that are derived using this technology
secondly<00:01:20.249> you<00:01:20.399> can<00:01:20.579> put<00:01:20.729> a<00:01:20.759> very<00:01:21.029> small<00:01:21.329> number

00:01:21.379 --> 00:01:21.389 
secondly you can put a very small number

00:01:21.389 --> 00:01:23.599 
secondly you can put a very small number
of<00:01:21.749> these<00:01:22.020> cells<00:01:22.350> into<00:01:22.709> a<00:01:22.740> very<00:01:23.039> localized

00:01:23.599 --> 00:01:23.609 
of these cells into a very localized

00:01:23.609 --> 00:01:25.789 
of these cells into a very localized
area<00:01:24.119> and<00:01:24.509> you<00:01:24.600> do<00:01:24.749> not<00:01:24.899> have<00:01:25.109> to<00:01:25.259> expect<00:01:25.740> the

00:01:25.789 --> 00:01:25.799 
area and you do not have to expect the

00:01:25.799 --> 00:01:27.199 
area and you do not have to expect the
cells<00:01:26.100> to<00:01:26.249> do<00:01:26.369> anything<00:01:26.609> more<00:01:26.909> than<00:01:26.969> they

00:01:27.199 --> 00:01:27.209 
cells to do anything more than they

00:01:27.209 --> 00:01:30.199 
cells to do anything more than they
naturally<00:01:27.749> do<00:01:27.959> they're<00:01:28.829> injected<00:01:29.789> beneath

00:01:30.199 --> 00:01:30.209 
naturally do they're injected beneath

00:01:30.209 --> 00:01:32.499 
naturally do they're injected beneath
the<00:01:31.139> retina<00:01:31.469> and<00:01:31.619> the<00:01:31.709> patients<00:01:32.189> and

00:01:32.499 --> 00:01:32.509 
the retina and the patients and

00:01:32.509 --> 00:01:35.419 
the retina and the patients and
eventually<00:01:33.509> populate<00:01:34.079> the<00:01:34.560> tissue<00:01:35.069> that's

00:01:35.419 --> 00:01:35.429 
eventually populate the tissue that's

00:01:35.429 --> 00:01:38.089 
eventually populate the tissue that's
been<00:01:35.549> lost<00:01:35.969> and<00:01:36.380> essentially<00:01:37.380> allow<00:01:38.039> the

00:01:38.089 --> 00:01:38.099 
been lost and essentially allow the

00:01:38.099 --> 00:01:41.149 
been lost and essentially allow the
patient<00:01:38.399> have<00:01:38.789> new<00:01:39.719> pigment<00:01:40.529> epithelium<00:01:41.009> that

00:01:41.149 --> 00:01:41.159 
patient have new pigment epithelium that

00:01:41.159 --> 00:01:45.710 
patient have new pigment epithelium that
will<00:01:41.249> replace<00:01:41.639> the<00:01:41.959> diseased<00:01:42.959> or<00:01:43.380> dead<00:01:44.159> tissue

00:01:45.710 --> 00:01:45.720 
will replace the diseased or dead tissue

00:01:45.720 --> 00:01:52.120 
will replace the diseased or dead tissue
a<00:01:48.230> CTS<00:01:49.230> conducted<00:01:49.980> several<00:01:50.700> trials<00:01:51.060> phase<00:01:51.660> one

00:01:52.120 --> 00:01:52.130 
a CTS conducted several trials phase one

00:01:52.130 --> 00:01:56.060 
a CTS conducted several trials phase one
two<00:01:53.130> trials<00:01:53.640> for<00:01:54.180> patients<00:01:54.600> who've<00:01:54.720> got<00:01:55.070> forms

00:01:56.060 --> 00:01:56.070 
two trials for patients who've got forms

00:01:56.070 --> 00:01:57.880 
two trials for patients who've got forms
of<00:01:56.250> macular<00:01:56.430> degeneration<00:01:56.700> that<00:01:57.480> are<00:01:57.600> either

00:01:57.880 --> 00:01:57.890 
of macular degeneration that are either

00:01:57.890 --> 00:02:00.830 
of macular degeneration that are either
inherited<00:01:58.890> such<00:01:59.670> as<00:01:59.820> Stargardt's<00:02:00.330> disease<00:02:00.330> a

00:02:00.830 --> 00:02:00.840 
inherited such as Stargardt's disease a

00:02:00.840 --> 00:02:02.930 
inherited such as Stargardt's disease a
juvenile<00:02:01.410> for<00:02:01.680> macular<00:02:01.980> degeneration<00:02:02.280> as

00:02:02.930 --> 00:02:02.940 
juvenile for macular degeneration as

00:02:02.940 --> 00:02:05.300 
juvenile for macular degeneration as
well<00:02:03.750> as<00:02:04.020> a<00:02:04.050> more<00:02:04.410> common<00:02:04.710> form<00:02:05.100> which<00:02:05.280> is

00:02:05.300 --> 00:02:05.310 
well as a more common form which is

00:02:05.310 --> 00:02:07.640 
well as a more common form which is
age-related<00:02:05.880> macular<00:02:06.510> degeneration<00:02:06.650> human

00:02:07.640 --> 00:02:07.650 
age-related macular degeneration human

00:02:07.650 --> 00:02:09.020 
age-related macular degeneration human
embryonic<00:02:07.980> stem<00:02:08.310> cells<00:02:08.520> were<00:02:08.610> discovered

00:02:09.020 --> 00:02:09.030 
embryonic stem cells were discovered

00:02:09.030 --> 00:02:10.370 
embryonic stem cells were discovered
over<00:02:09.240> three<00:02:09.390> decades<00:02:09.540> ago<00:02:10.050> and<00:02:10.290> are

00:02:10.370 --> 00:02:10.380 
over three decades ago and are

00:02:10.380 --> 00:02:11.900 
over three decades ago and are
considered<00:02:10.770> a<00:02:10.860> promising<00:02:11.310> source<00:02:11.520> of<00:02:11.670> cells

00:02:11.900 --> 00:02:11.910 
considered a promising source of cells

00:02:11.910 --> 00:02:13.880 
considered a promising source of cells
for<00:02:12.120> regenerative<00:02:12.570> medicine<00:02:12.870> this<00:02:13.650> paper

00:02:13.880 --> 00:02:13.890 
for regenerative medicine this paper

00:02:13.890 --> 00:02:16.040 
for regenerative medicine this paper
reports<00:02:14.130> for<00:02:14.850> the<00:02:14.880> first<00:02:15.120> time<00:02:15.360> evidence<00:02:15.900> of

00:02:16.040 --> 00:02:16.050 
reports for the first time evidence of

00:02:16.050 --> 00:02:17.900 
reports for the first time evidence of
their<00:02:16.170> long-term<00:02:16.560> survival<00:02:17.070> as<00:02:17.400> well<00:02:17.820> as

00:02:17.900 --> 00:02:17.910 
their long-term survival as well as

00:02:17.910 --> 00:02:19.670 
their long-term survival as well as
potential<00:02:18.330> efficacy<00:02:18.540> in<00:02:18.959> humans<00:02:19.320> with<00:02:19.440> any

00:02:19.670 --> 00:02:19.680 
potential efficacy in humans with any

00:02:19.680 --> 00:02:21.620 
potential efficacy in humans with any
disease<00:02:20.070> really<00:02:20.670> importantly<00:02:21.120> the<00:02:21.330> cells

00:02:21.620 --> 00:02:21.630 
disease really importantly the cells

00:02:21.630 --> 00:02:24.680 
disease really importantly the cells
themselves<00:02:22.100> have<00:02:23.100> no<00:02:23.370> apparent<00:02:24.030> adverse

00:02:24.680 --> 00:02:24.690 
themselves have no apparent adverse

00:02:24.690 --> 00:02:27.470 
themselves have no apparent adverse
effect<00:02:25.050> on<00:02:25.200> the<00:02:25.320> patients<00:02:25.800> in<00:02:25.950> the<00:02:26.880> context<00:02:27.390> of

00:02:27.470 --> 00:02:27.480 
effect on the patients in the context of

00:02:27.480 --> 00:02:30.410 
effect on the patients in the context of
the<00:02:27.600> safety<00:02:28.020> trial<00:02:28.350> it<00:02:29.250> was<00:02:29.430> essentially

00:02:30.410 --> 00:02:30.420 
the safety trial it was essentially

00:02:30.420 --> 00:02:33.080 
the safety trial it was essentially
beyond<00:02:30.780> our<00:02:31.400> thoughts<00:02:32.400> that<00:02:32.760> we<00:02:32.910> would

00:02:33.080 --> 00:02:33.090 
beyond our thoughts that we would

00:02:33.090 --> 00:02:34.670 
beyond our thoughts that we would
actually<00:02:33.209> see<00:02:33.540> improvements<00:02:34.260> in<00:02:34.350> visual

00:02:34.670 --> 00:02:34.680 
actually see improvements in visual

00:02:34.680 --> 00:02:38.840 
actually see improvements in visual
acuity<00:02:34.950> however<00:02:37.040> importantly<00:02:38.040> no<00:02:38.490> patient

00:02:38.840 --> 00:02:38.850 
acuity however importantly no patient

00:02:38.850 --> 00:02:41.600 
acuity however importantly no patient
lost<00:02:39.000> vision<00:02:39.330> and<00:02:40.080> in<00:02:40.260> some<00:02:40.440> cases<00:02:40.709> visions

00:02:41.600 --> 00:02:41.610 
lost vision and in some cases visions

00:02:41.610 --> 00:02:43.850 
lost vision and in some cases visions
was<00:02:42.360> enhanced<00:02:42.870> in<00:02:43.170> the<00:02:43.410> number<00:02:43.680> of<00:02:43.709> the

00:02:43.850 --> 00:02:43.860 
was enhanced in the number of the

00:02:43.860 --> 00:02:47.510 
was enhanced in the number of the
patients<00:02:44.900> the<00:02:45.900> publication<00:02:46.650> of<00:02:46.890> this<00:02:47.100> data<00:02:47.310> in

00:02:47.510 --> 00:02:47.520 
patients the publication of this data in

00:02:47.520 --> 00:02:49.310 
patients the publication of this data in
The<00:02:47.610> Lancet<00:02:47.730> is<00:02:48.150> extremely<00:02:48.690> important<00:02:49.110> for<00:02:49.140> a

00:02:49.310 --> 00:02:49.320 
The Lancet is extremely important for a

00:02:49.320 --> 00:02:51.800 
The Lancet is extremely important for a
CT<00:02:49.680> it's<00:02:49.920> the<00:02:50.070> first<00:02:50.340> time<00:02:50.700> that<00:02:50.760> any<00:02:51.510> company

00:02:51.800 --> 00:02:51.810 
CT it's the first time that any company

00:02:51.810 --> 00:02:54.140 
CT it's the first time that any company
has<00:02:52.110> been<00:02:52.230> able<00:02:52.440> to<00:02:52.560> show<00:02:52.820> extended<00:02:53.820> step

00:02:54.140 --> 00:02:54.150 
has been able to show extended step

00:02:54.150 --> 00:02:57.740 
has been able to show extended step
safety<00:02:54.630> of<00:02:54.900> cell<00:02:55.320> therapy<00:02:56.300> we're<00:02:57.300> a<00:02:57.330> leading

00:02:57.740 --> 00:02:57.750 
safety of cell therapy we're a leading

00:02:57.750 --> 00:02:59.630 
safety of cell therapy we're a leading
company<00:02:57.900> in<00:02:58.170> regenerative<00:02:58.650> ophthalmology

00:02:59.630 --> 00:02:59.640 
company in regenerative ophthalmology

00:02:59.640 --> 00:03:01.729 
company in regenerative ophthalmology
and<00:02:59.810> there<00:03:00.810> were<00:03:00.900> just<00:03:00.930> about<00:03:01.170> to<00:03:01.320> start<00:03:01.560> our

00:03:01.729 --> 00:03:01.739 
and there were just about to start our

00:03:01.739 --> 00:03:03.800 
and there were just about to start our
phase<00:03:01.920> 2<00:03:02.130> clinical<00:03:02.280> programs<00:03:03.000> for<00:03:03.540> both<00:03:03.660> of

00:03:03.800 --> 00:03:03.810 
phase 2 clinical programs for both of

00:03:03.810 --> 00:03:06.260 
phase 2 clinical programs for both of
these<00:03:03.900> disorders

